These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 32017220)
1. Severe asthma in children: Current goals and unmet needs. Licari A; Manti S; Chiappini E; Ciprandi G; Marseglia GL Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():40-42. PubMed ID: 32017220 [TBL] [Abstract][Full Text] [Related]
2. Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: A Practical Review. Votto M; De Filippo M; Licari A; Marseglia A; De Amici M; Marseglia GL Biologics; 2021; 15():133-142. PubMed ID: 33981139 [TBL] [Abstract][Full Text] [Related]
3. IgE and eosinophils as therapeutic targets in asthma. Patel TR; Sur S Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698 [TBL] [Abstract][Full Text] [Related]
4. Severe asthma: When to resort to biological agents. Tenero L; Rossignoli S; Piacentini G Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206 [TBL] [Abstract][Full Text] [Related]
5. Omalizumab in the Therapy of Pediatric Asthma. Poddighe D; Brambilla I; Licari A; Marseglia GL Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):103-109. PubMed ID: 29714140 [TBL] [Abstract][Full Text] [Related]
6. Immunological biomarkers in severe asthma. Narendra D; Blixt J; Hanania NA Semin Immunol; 2019 Dec; 46():101332. PubMed ID: 31735516 [TBL] [Abstract][Full Text] [Related]
7. Asthma Phenotypes as a Guide for Current and Future Biologic Therapies. Hamilton D; Lehman H Clin Rev Allergy Immunol; 2020 Oct; 59(2):160-174. PubMed ID: 31359247 [TBL] [Abstract][Full Text] [Related]
8. Relevance of TH2 Markers in the Assessment and Therapeutic Management of Severe Allergic Asthma: A Real-Life Perspective. Caminati M; Vianello A; Chieco Bianchi F; Festi G; Guarnieri G; Marchi MR; Micheletto C; Olivieri M; Tognella S; Guerriero M; Senna G; J Investig Allergol Clin Immunol; 2020; 30(1):35-41. PubMed ID: 30676321 [TBL] [Abstract][Full Text] [Related]
9. Severe asthma in children: therapeutic considerations. Selby L; Saglani S Curr Opin Allergy Clin Immunol; 2019 Apr; 19(2):132-140. PubMed ID: 30720474 [TBL] [Abstract][Full Text] [Related]
10. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study. Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296 [TBL] [Abstract][Full Text] [Related]
11. Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. Baena-Cagnani CE; Teijeiro A; Canonica GW Curr Opin Allergy Clin Immunol; 2015 Jun; 15(3):267-71. PubMed ID: 25899697 [TBL] [Abstract][Full Text] [Related]
12. Antibody therapy for the management of severe asthma with eosinophilic inflammation. Ohta K; Nagase H; Suzukawa M; Ohta S Int Immunol; 2017 Jul; 29(7):337-343. PubMed ID: 28910970 [TBL] [Abstract][Full Text] [Related]
13. Biomarkers for severe allergic asthma in children: could they be useful to guide disease control and use of omalizumab? Amat F; Labbé A Expert Rev Respir Med; 2018 Jun; 12(6):475-482. PubMed ID: 29741411 [TBL] [Abstract][Full Text] [Related]
14. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052 [TBL] [Abstract][Full Text] [Related]
15. Predicting asthma morbidity in children using proposed markers of Th2-type inflammation. Konradsen JR; Skantz E; Nordlund B; Lidegran M; James A; Ono J; Ohta S; Izuhara K; Dahlén SE; Alving K; Hedlin G Pediatr Allergy Immunol; 2015 Dec; 26(8):772-9. PubMed ID: 26266838 [TBL] [Abstract][Full Text] [Related]
16. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533 [TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Management of Severe Asthma. Chung KF Semin Respir Crit Care Med; 2018 Feb; 39(1):91-99. PubMed ID: 29427989 [TBL] [Abstract][Full Text] [Related]
18. dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. Palomares Ó; Sánchez-Ramón S; Dávila I; Prieto L; Pérez de Llano L; Lleonart M; Domingo C; Nieto A Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635659 [TBL] [Abstract][Full Text] [Related]
19. The discovery and development of omalizumab for the treatment of asthma. Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110 [TBL] [Abstract][Full Text] [Related]
20. Options of immunotherapeutic treatments for children with asthma. Porcaro F; Cutrera R; Pajno GB Expert Rev Respir Med; 2019 Oct; 13(10):937-949. PubMed ID: 31414917 [No Abstract] [Full Text] [Related] [Next] [New Search]